Small Pharma Inc., a U.K.-based company involved in developing short-acting psychedelics, has been dedicated to securing proprietary intellectual property (IP) across North America, Australasia, and Europe. CEO George Tziras stated that the company has made considerable progress in strengthening its IP position by creating multi-layered IP protection and optimizing each pipeline program’s commercial potential.
Small Pharma’s protection strategy includes discovering innovative drugs, their therapeutic compositions and medical uses, as well as synthesizing high-purity drug substances at scale.
Since February, Small Pharma has been granted five new patents, which include two covering the composition of matter for deuterated tryptamine homologs, one covering the novel synthesis of high-purity DMT and deuterated DMT analogs on a large scale, one for a unique injectable formulation of DMT-based compounds, and finally, one for therapeutic solid dosage forms of deuterated DMT analogs.
Additionally, three more patents covering the composition of matter of specific deuterated DMT analogs and deuterated DMT homologs that have medical use are expected to be granted by May 31.
Small Pharma has also received five notices of allowance on patents covering the composition of matter for a group of deuterated DMT homologs, medical usage, and therapeutic compositions of deuterated DMT homologs, and the novel synthesis of high-purity DMT and deuterated DMT analogs at scale.
Small Pharma’s psychedelic IP portfolio comprises 14 approved patents with 87 granted or pending patents. The drug development pipeline encompasses intravenous/intramuscular DMT compound SPL026, injectable deuterated DMT series SPL028, and oral tryptamine series SPL029.
